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Abstract
The World Health Organization estimates that 1 billion cases of infectious 
disease originate from vector transmission, resulting in several million 
deaths annually. Mosquitos are the primary vector for multiple diseases in 
humans that cause self-limiting to sight-threatening ocular complications 
and significant systemic illness. The 2015-2016 outbreak of the mosquito-
borne Zika virus in North and South America brought to the forefront 
how quickly mosquitoes can spread disease between continents, especially 
among vulnerable patient populations. Optometrists should be familiar 
with the associated ocular complications in order to effectively diagnose, 
co-manage, treat, and educate patients who have been infected by mosqui-
to-borne disease. This paper reviews the ocular manifestations of mosqui-
to-transmitted diseases including Zika virus, West Nile virus, Malaria, Den-
gue fever, Chikungunya, and Dirofilaria.
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INTRODUCTION
Mosquitoes are known vectors for certain infectious diseases that can be 
transmitted from animals to humans or between humans. When feeding 
on the blood of an infected organism, the mosquito can acquire a virus or 
a parasite, which can then be injected into another human during a subse-
quent blood meal. Aided by factors such as the globalization of travel, en-
vironmental challenges like climate change, and the urbanization of rural 
areas, mosquito-transmitted diseases such as Dengue fever, Chikungunya 
and West Nile virus have been found for the first time in certain countries.1 
The 2016 outbreak of the mosquito-borne Zika virus in North and South 
America exemplifies how quickly mosquitoes can spread disease between 
continents, causing significant health risks in vulnerable patient popula-
tions, such as pregnant women.2 With this increase in the prevalence of 
mosquito-borne disease, it is imperative for healthcare providers to stay 
informed about the associated clinical signs and complications. This pa-
per reviews published literature on the ocular manifestations of mosquito-
transmitted diseases including Zika virus, West Nile virus, malaria, Dengue 
fever, Chikungunya, and Dirofilaria (summarized in Table 1). 
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Table 1: Ocular Manifestations of Mosquito-Transmitted Diseases
Disease Transmission
Endemic areas with 
active transmission
Vaccine 
available
Ocular manifestations
Zika virus 
(ZIKV)
Mosquito Vector:
Aedes aegypti or Aedes 
albopictus mosquitos
• Sexual intercourse with  
an infected individual
• Maternal-fetal transmission 
Mexico
Central America
South America
New Guinea
No
Fetal
Focal pigment mottling of the retina 
Chorioretinal atrophy
Macular atrophy
Cataract
Asymmetrical eye sizes
Intraocular calcifications
Optic nerve abnormalities 
Lens subluxation
Adults
Guillain-Barré syndrome, which is 
associated with various ocular muscle 
palsies and non-purulent conjunctivitis
West Nile 
virus
(WNV)
Mosquito vector: 
64 types of mosquito species 
carry WNV. The most 
common species are the 
Aedes and Culex mosquitoes. 
Virus is acquired after a 
mosquito feeds on an infected 
bird. 
• Low risk of maternal-fetal 
transmission or through 
blood transfusions. 
Europe, Middle East, 
West Asia, North 
America, South 
America,  
and Australia
No
Retinal hemorrhages
Vitritis
Perivascular sheathing
Vasculitis
Disc edema
Optic atrophy
Vascular occlusion
Sixth nerve palsy
Uveitis
Ocular complications associated with 
meningoencephalitis secondary to WNV 
Acute hemorrhagic conjunctivitis
Bilateral subconjunctival hemorrhages
Nystagmus
Fetal
Chorioretinal involvement
Malaria
Mosquito vector: 
Anopheles mosquito
• Blood transfusion, organ  
transplant, or the shared  
use of needles or syringes 
contaminated with blood
• Maternal-fetal transmission
Highest transmission 
is found in Africa 
south of the  
Sahara and in  
parts of Oceania 
such as Papua  
New Guinea
Vaccine 
clinical 
trials are 
ongoing 
Antimalarial 
drugs are 
available
Ocular complications are generally 
associated with cerebral malaria (CM) 
Retinal whitening in the periphery and 
macula (sparing the fovea)
Peripheral orange or white vessel 
discoloration 
Roth’s spots
Papilledema 
Cotton wool spots 
Dengue 
fever (DF)
Mosquito vector: Aedes 
aegypti mosquito
• Dengue cannot be spread 
directly from person to 
person
Tropical countries 
such as Southeast 
Asia, India, and  
the American 
Tropics
No
Retinal hemorrhages
Macular edema
Foveolitis
Vasculitis
Optic neuropathy
Subconjunctival hemorrhages
Uveitis
Angle closure glaucoma
Chikungunya
Mosquito vector: Aedes 
aegypti and Aedes albopictus 
mosquitos
• Rarely from mother to  
newborn around the time of 
birth
• While, in theory, the virus 
could be spread through a 
blood transfusion, to date, 
there are no known reports.
Africa, Asia,  
Europe, islands  
in the Caribbean,  
the Indian and 
Pacific Oceans
No
Conjunctival injection
Photophobia
Anterior and posterior inflammation 
Secondary complications of ocular 
inflammation
Sixth nerve palsy
Central retinal artery occlusion (CRAO)
Exudative retinal detachment
Glaucoma
Dirofilaria 
repens (DR)
Mosquito Vector:
Aedes, Anopheles, Mansonia, 
or Culex mosquitos
Warm climates on 
various continents, 
in Europe mainly 
in Mediterranean 
countries
No
Ophthalmic subcutaneous lesions 
usually causing pain and redness
Eyelid 
Periorbital
Subconjunctival 
Subtenons 
Intraocular
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ZIK A VIRUS
The Zika virus (ZIKV) is a flavivirus that is transmitted primarily by Aedes aegypti mosquitoes and was first iden-
tified in humans in 1952.2 The 2016 ZIKV epidemic in Brazil likely originated from French Polynesia and subse-
quently spread from South America to Central and North America. If infected, a person may display symptoms 
such as fever for a short amount of time, rash, joint pain, or conjunctivitis.2 In February of 2016, the World Health 
Organization considered the ZIKV outbreak to be a “Public Health Emergency of International Concern” based on 
the microcephaly and neurological disorders associated with the disease.3
Pregnant women are most susceptible to maternal-fetal transmission when exposed to ZIKV in the first or second 
trimester. Circumstantial evidence suggests that fetal manifestations of ZIKV infection may be induced by cho-
lestatic liver damage resulting in the leakage of toxic concentrations of vitamin A compounds (Hypervitaminosis 
A) into the maternal and fetal circulation. Hypervitaminosis A is speculated to cause overall fetal growth arrest, 
microcephaly, and other congenital anomalies. Due to the general association of microcephaly and ocular complica-
tions, comprehensive eye examinations are recommended in microcephalic infants. Unilateral and bilateral retinal 
pathology has been documented in microcephalic infants, most commonly as focal pigment mottling of the retina 
and chorioretinal atrophy. Other reported ophthalmic findings have included macular atrophy, iris coloboma with 
lens subluxation, cataract, asymmetrical eye sizes, intraocular calcifications, and various optic nerve abnormalities.4 
It has also been shown that ZIKV can cause Guillain-Barré syndrome, an autoimmune disorder that can be associ-
ated with various ocular muscle palsies and non-purulent conjunctivitis in adults.5
ZIKV can be detected by performing real-time reverse transcription-polymerase chain reaction (rRT-PCR) on se-
rum or urine, or IgM testing on serum; however, these methods are not readily available in countries where the con-
dition is prevelant.2 Since there is no ZIKV vaccine or specific treatment for ZIKV, women living in endemic areas 
should consider these risks before conceiving and avoid travelling to regions where disease outbreak is evident.6 
ZIKV can also be transmitted through sexual intercourse with an infected partner since the virus remains in semen 
longer than in any other body fluid; therefore, appropriate precautions must be taken.2 
WEST NILE VIRUS
A variety of mosquitoes transmit the flavivirus which is responsible for West Nile virus (WNV) from infected birds 
to humans. The virus first entered the western hemisphere in 1999 and is now prevalent in North America, especial-
ly during the summer months. It is estimated that 80% of WNV-infected individuals are asymptomatic; while 20% 
may exhibit flu-like symptoms, exact statistics vary.7,8 Patients infected by WNV are at risk of developing devastating 
neurological disease, which may manifest 3-14 days after infection. Clinical symptoms can range from generalized 
muscle weakness to high fever, stiff neck, and even convulsions. Adults aged 50 and older and individuals who are 
immunocompromised have a higher chance of developing neurological complications from WNV.7 
A multitude of ocular manifestations have been reported, including, but not limited to, retinal hemorrhages, vitritis, 
perivascular sheathing, vasculitis, disc edema, optic atrophy, vascular occlusion, sixth nerve palsy, and uveitis.8-10 In 
less than 1% of cases, an infected individual can develop WNV meningoencephalitis, which has been documented 
in the literature to be associated with ocular complications such as acute hemorrhagic conjunctivitis, bilateral sub-
conjunctival hemorrhages, and nystagmus.11 Chorioretinal involvement can also develop in a fetus via intrauterine 
virus transmission. One such case was documented in a newborn whose mother had contracted WNV two months 
before delivery.12 Current management of WNV includes pain control for headaches, anti-emetics, rehydration for 
associated nausea and vomiting, clinical monitoring for development of elevated intracranial pressure or autonomic 
dysfunction, and seizure control, if needed.13 
MAL ARIA 
Malaria is endemic to sub-Saharan Africa, where children are most vulnerable to contracting the disease due to 
their immature immune systems. It is mainly transmitted by the Anopheles mosquito, but can also be passed via 
a blood transfusion, an organ transplant, or the shared use of contaminated needles or syringes since the parasite 
resides in the red blood cells of an infected individual. Congenital malaria occurs when the parasite is transmitted 
before or during delivery from a mother to her child. The first presentation of clinical signs often occurs 10-15 days 
following infection by a mosquito bite. In the early stages of infection, the diagnosis of malaria may be difficult to 
make because of the generalized clinical presentation of fever and vomiting.1
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Several parasites in the Plasmodium genus infect humans with malaria, including P. falciparum, P. vivax, P. ovale, 
and P. malariae.14 P.falciparum causes cerebral malaria (CM), which has a high rate of mortality and is characterized 
by coma and long-term neuro-cognitive impairments.15 Some ocular complications can be noted with CM, since 
the retinal and cerebral vasculature are direct extensions of one another; therefore, monitoring retinal changes can 
provide an understanding of the neurological pathogenesis of CM and aid in determining the patient’s prognosis 
and, perhaps, better treatment strategies.16
CM retinopathy shows retinal whitening patterns and vessel changes that are unique to the disease. Both are mainly 
found in the peripheral retina with a white or orange discoloration of the vessels. Other retinal findings include 
cotton wool spots, papilledema, and Roth’s spots.16,17 Due to the distinctive retinal presentation of the disease, these 
findings can be useful in confirming the diagnosis of CM. In addition, the severity of retinopathy and papilledema 
may be an indicator of disease prognosis.15 If CM develops, the treatment of choice is the water-soluble artemisinin 
derivative artesunate and adjunctive supportive management of malaria complications.14,18,19
Currently, there are no effective malarial vaccines and multi-drug resistance is prevalent; therefore, travelers des-
tined for endemic regions are recommended to begin prophylactic treatment prior to departure and continue treat-
ment for a period of time after returning home. The recommended medications for prophylaxis and their associated 
treatment time frames vary depending on the country of travel.14
DENGUE FEVER
Dengue fever (DF) is a self-limiting condition transmitted by the Aedes aegypti mosquito. Female mosquitoes in-
fected with the dengue flavivirus are endemic to tropical countries, such as Southeast Asia, India, and the Ameri-
can tropics. As the name implies, infected individuals suffer from an acute onset of fever along with other general 
symptoms, such as malaise, sore throat, and headache.20,21 DF is potentially life-threatening in a small proportion of 
infected individuals and can cause severe hemorrhages, organ dysfunction, or plasma leakage. Patients with DF may 
also have a myriad of symptomatic anterior and posterior segment ocular complications resulting in blurred vision 
and scotomas. Such symptoms may indicate thrombocytopenia and a need for early, aggressive treatment; however, 
there is no specific therapy for DF itself.21 
Blurry vision is the most commonly reported dengue-related ocular symptom, followed by scotoma and ocular pain, 
which can be diffuse or retrobulbar. The ocular complications of this disease are more commonly found within the 
posterior segment, particularly involving the macula. Manifestations include retinal hemorrhages, macular edema, 
foveolitis, vasculitis, vascular occlusion and optic neuropathy. Anterior segment complications include subconjunc-
tival hemorrhages, uveitis with and without ciliary congestion, and shallowing of the anterior chamber angle with 
the risk of acute angle closure. Patients with severe vision loss or bilateral involvement can be treated with systemic 
steroids, and occasionally immunoglobulins, to minimize inflammatory damage; however, most dengue-related 
ophthalmic complications resolve without treatment.20 Since no vaccines or specific medications are available to 
treat DF, precautions should be taken when traveling to areas where the virus is endemic.22
CHIKUNGUNYA
Chikungunya fever is caused by the Chikungunya virus and is most often spread by Aedes aegypti and Aedes albop-
ictus mosquitoes. After a quiescent period, this virus re-emerged over the last decade in several regions including 
Africa, North and South America, Asia, Europe, and the Indian and Pacific Oceans.23 The symptoms associated with 
this infection include an abrupt onset of severe joint pain, which can be debilitating, fever, chills, headache, muscle 
ache, and rash. The onset of symptoms typically occurs 4 to 8 days following infection by the mosquito.7 
Ocular inflammation is a documented complication of Chikungunya fever and commonly presents as granulomatous 
or non-granulomatous anterior uveitis. Infected individuals may also present with conjunctival injection and photo-
phobia. There have also been reports of keratitis, episcleritis, retinitis with vitritis, neuroretinitis, multifocal choroidi-
tis, panuveitis, and optic neuritis. Secondary complications of ocular inflammation include sixth nerve palsy, central 
retinal artery occlusion, exudative retinal detachment, and glaucoma.24 Chikungunya fever-related ocular inflamma-
tion responds well to corticosteroid therapy over a period of 6-12 weeks and, if treated early, can resolve with a good 
visual outcome.24,25 Management of systemic symptoms includes pain reduction and dehydration prevention. 
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There is no vaccine to prevent infection by the Chikungunya virus; therefore, to limit the spread of the virus, in-
fected individuals should take precautions against mosquito bites. The virus is present in the blood during the first 
week of infection and can be transmitted to mosquitoes and other people during that time.23
DIROFIL ARIASIS
Human dirofilariasis is a rare vector-borne zoonotic disease that is commonly caused by Dirofilaria repens and Diro-
filaria immitus. D. repens is a subcutaneous parasite of domestic animals in warm and moist climates. The disease is 
transmitted to humans through the bite of an infected Aedes, Anopheles, Mansonia or Culex mosquito.26-28 Symptoms 
of D. repens include benign subcutaneous lesions on the face, chest wall, upper arms, thighs, abdominal wall, and 
male genitalia. Between 30-35% of D. repens-related infections occur in the ocular regions. 
Most cases of ocular dirofilariasis involve infestations of the periocular tissue. In approximately 60% of the human cases 
reported, the parasites were located under the conjunctiva within nodules or cysts that grow over time.29 Lesions may also 
be found on the eyelid where they have been reported to cause preseptal cellulitis. Symptoms depend on the site of the 
infection, but typically include pain and redness.27 The treatment for ocular dirofilariasis is complete excision of the le-
sion. Definitive diagnosis is confirmed by histopathologic and microscopic examination of the surgically excised worm.30
PREVENTION
The number of humans infected by mosquito-transmitted diseases may increase secondary to multiple factors such 
as the globalization of travel, and social and environmental issues.1 Early containment of outbreaks is key to reduc-
ing the transmission and spread of these diseases. The World Health Organization continues to assist countries 
through enhanced disease surveillance, the development of new mechanisms to reduce the spread of disease, and 
education on disease recognition. 
The ocular manifestations caused by mosquito-borne diseases can range from self-limiting to vision-threatening. 
Optometrists play an important role in the clinical co-management of patients infected by mosquito-borne illness, 
in collaboration with infectious disease specialists. To aid in early diagnosis and minimize morbidity, optometrists 
should inquire about recent travel to any endemic regions for patients exhibiting systemic symptoms, such as a fever 
with an associated complaint of blurred vision and/or ocular discomfort. 
Unfortunately, no vaccines or drugs are available to treat most of these mosquito-transmitted diseases; therefore, 
those travelling to high-risk countries should be educated on mosquito bite prevention, including the use of Envi-
ronmental Protection Agency (EPA)-approved mosquito repellants, mosquito bed nets, and window/door screens, 
and ensuring that both indoor and outdoor environments do not support standing water where mosquitoes typi-
cally lay their eggs.22,31,32 Furthermore, vulnerable patient populations, such as pregnant women, young children, and 
the immunocompromised, should avoid travel to areas of disease outbreak. In cases where travel is unavoidable, 
awareness of the common manifestations of a mosquito-transmitted disease is imperative so that infected individu-
als will seek immediate medical attention if they experience any correlating symptoms.1,2,7 l
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